PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry.
Participants will be recruited \& screened over a five-year period. Study participants will be asked to provide a saliva sample to be tested for germline cancer risk variants through Color Health. If the results identify a pathogenic or likely pathogenic variant, an appointment with a genetic counselor from Color Health will be scheduled to discuss the results.
Participants will complete a baseline demographic survey that includes self-reported health history, family history of cancer and standardized patient reported outcome (PRO) measures.
PROMISE Registry staff will request medical records from the participant's cancer care provider(s) for the purpose of obtaining clinical data.
Participants will receive bi-annual newsletters offering information on new developments in treatment and research opportunities, including clinical trials, associated with genetic variants.
Eligible participants (those with target germline mutations) will be followed every 6 months to obtain updated health records data and patient-reported outcomes data. Participants will be followed for a minimum of 15 years.
The PROMISE registry will help identify prostate cancer patients with pathogenic variants to learn more about how these variants affect patient outcomes. Ultimately, we hope to help patients learn more about their disease and the treatments that they may derive the most benefit from, including the germline genetic biomarker-based clinical trials they may be eligible for.
For more information, visit the study website at: prostatecancerpromise.org
tissue biopsy, and/or
PSA greater than 100 ng/dL (1ng/ml), and/or
clear radiographic evidence of disease
Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands)
Unable or unwilling to provide all of the necessary information for eligibility
Incomplete inclusion criteria
Individuals with prostate cancer (any stage of disease or survivorship). Individuals are eligible whether they have had prior germline genetic testing or not.
Cohort
Prospective
Not listed
Frequency of at least one germline pathogenic or likely pathogenic variant
Frequency of having at least one germline pathogenic or likely pathogenic variant in a cancer risk gene based on the number of subjects screened.
Frequency of pathogenic or likely pathogenic germline variants of interest
Frequency of pathogenic or likely pathogenic germline variants of interest in subjects with prostate cancer. We will estimate the frequency of having each of the germline pathogenic or likely pathogenic variant in the cancer risk genes based on the number of subjects screened in each subpopulation.
Identify and recruit control group of patients with a variant of uncertain significance (VUS)
Identify and recruit a control group of patients with a VUS in their clinical or research results in the following genes: ATM, ATR, BARD1, BRCA1, BRCA2, FAM175A, GEN1, HOXB13, MRE11A, PALB2 and XRCC2.
Association between disease characteristics and genetic variants
Collect data on disease characteristics and examine the association between disease characteristics and pathogenic and likely pathogenic germline variants and VUS of interest.
Analysis of patient reported outcomes (PRO) measures
Collect PRO measures associated with genetic testing in subjects with prostate cancer using the validated EORTC QLQ-C30.
Click on the lead sponsor to view all of their trials.
Prostate Cancer Clinical Trials Consortium
Lead sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
Fred Hutchinson Cancer Center
Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborator
Advancing Cancer Treatment, Inc.
Collaborator
